Logo Logo
Switch Language to German

Tamalunas, Alexander; Schulz, Gerald B.; Rodler, Severin; Apfelbeck, Maria; Stief, Christian G. and Casuscelli, Jozefina (2021): Systemtherapie des Harnblasenkarzinoms. In: Urologe, Vol. 60, No. 2: pp. 247-258

Full text not available from 'Open Access LMU'.


With around 30,000 new cases annually bladder cancer (BC) is one of the most frequent cancers in Germany and the incidence is associated with advanced age and nicotine use. Urothelial carcinoma is the most frequent histological variant of BC in Central Europe. Nonmuscle-invasive BC can be resected endourologically and treated with intravesical instillation therapy. In the case of progression to nonmetastatic muscle-invasive disease radical cystectomy with accompanying neoadjuvant or adjuvant chemotherapy can be curative. Systemic treatment is the standard of care in metastatic disease. Although immunotherapy has made great progress in recent years, palliative chemotherapy remains the gold standard in first-line treatment. The armamentarium is continuously evolving: systemic immunotherapy is currently being investigated in nonmuscle-invasive BC as well as in perioperative and maintenance treatment after first-line chemotherapy and several studies are testing new targeted agents in palliative systemic therapy. This article gives an overview of current innovations and the expected paradigm shift in systemic treatment of BC.

Actions (login required)

View Item View Item